Literature DB >> 159124

Concanavalin A-inducible suppressor cells in regional lymph nodes of cancer patients.

W J Catalona, T L Ratliff, R E McCool.   

Abstract

Regional tumor-draining lymph nodes of 11 of 14 patients with urological tumors and one of four controls studied contained suppressor cell precursors that could be activated by concanavalin A (Con A) to suppress the proliferative response of autologous lymphocytes to Con A. In contrast, no suppression of lymphocyte proliferation by lymph node cells that were not activated with Con A was observed in four patients tested. The suppressive effect was not due to decreased viability or increased release of cold thymidine by Con A-activated cells nor to alteration in the time course of the proliferative response of Con A-activated cells. Mitomycin C treatment of lymph node cells 24 hr after activation did not abrogate their suppressive activity. Peak suppression was observed after 72 hr in culture. The amount of suppression measured could be maximized by treatment of suppressor cells with mitomycin C 24 hr after activation and by washing the cells immediately before pulse labeling with tritiated thymidine. The concentration of Con A required to produce peak suppression varied from patient to patient with optimal doses ranging from 5 to 25 microgram/ml.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 159124

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  The significance of relationship of the presence of nonspecific suppressor cells in spleens with gastric cancer-related pathology.

Authors:  Y Kurosu; S Fukamachi; K Morita
Journal:  Jpn J Surg       Date:  1984-07

2.  Induction of suppressor cell activities in normal lymphocytes by sera from gastric cancer patients.

Authors:  T Toge; M Tanada; K Yajima; H Kohno; E Itagaki; T Hattori
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

3.  Immune studies by the use of Multitest-Merieux in patients with kidney tumours.

Authors:  I Romics; D Répássy; G Kulcsár; P Brühl
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

4.  Lymph node proliferation in patients with urological tumours.

Authors:  H D Adolphs; H W Schwabe
Journal:  Urol Res       Date:  1983

5.  Peripheral blood and tumor-infiltrating mononuclear cell analysis in esophagus and head and neck cancer.

Authors:  P Lozac'h; P Corbeau; C Zabbe; J F Charles; P Youinou
Journal:  Med Oncol Tumor Pharmacother       Date:  1987

6.  Mitogen responsiveness and inhibitory activity of mesenteric lymph node cells. Conditioned medium containing T cell growth factor reverses suppressor function.

Authors:  B M Vose; R Ferguson; M Moore
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

7.  Role of the spleen on immunosuppression in esophageal and gastric cancer.

Authors:  T Toge; A Kameda; H Yamada; Y Seto; K Aratani; T Fujita; T Hattori
Journal:  Jpn J Surg       Date:  1986-09

8.  Concanavalin A induced suppressor cell activity and autorosette forming cells in chronic myeloid leukemia patients.

Authors:  R Somasundaram; S H Advani; S G Gangal
Journal:  Br J Cancer       Date:  1983-12       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.